AAPL336.91+3.89 (+1.17%) ▲|ABBV256.91-2.45 (-0.94%) ▼|ABT104.49+1.43 (+1.39%) ▲|ACN154.06+7.07 (+4.81%) ▲|ADBE237.75+12.64 (+5.62%) ▲|AMAT516.89-19.36 (-3.61%) ▼|AMD494.95-27.00 (-5.17%) ▼|AMGN376.26+0.22 (+0.06%) ▲|AMT166.74+0.07 (+0.04%) ▲|AMZN231.39-0.72 (-0.31%) ▼|AVGO383.22+1.30 (+0.34%) ▲|AXP335.39+9.22 (+2.83%) ▲|BA211.50+1.98 (+0.95%) ▲|BAC62.13+0.08 (+0.13%) ▲|BKNG186.79+9.33 (+5.26%) ▲|BLK1,062.14+6.47 (+0.61%) ▲|BMY62.56+0.47 (+0.76%) ▲|BNY157.77-0.51 (-0.32%) ▼|BRK-B497.18+2.25 (+0.45%) ▲|C133.10+0.91 (+0.69%) ▲|CAT873.28-15.45 (-1.74%) ▼|CL91.98+1.23 (+1.36%) ▲|CMCSA22.80+0.51 (+2.27%) ▲|COF207.05+4.21 (+2.08%) ▲|COP115.58-4.68 (-3.89%) ▼|COST951.58+16.55 (+1.77%) ▲|CRM173.60+9.94 (+6.07%) ▲|CSCO114.57+0.40 (+0.35%) ▲|CVS107.07-0.67 (-0.62%) ▼|CVX190.00-4.79 (-2.46%) ▼|DE625.02-3.14 (-0.50%) ▼|DHR196.50+5.00 (+2.61%) ▲|DIS96.65+1.80 (+1.90%) ▲|DUK128.83-1.69 (-1.29%) ▼|EMR149.30+1.36 (+0.92%) ▲|FDX310.79-4.17 (-1.32%) ▼|GD389.14+2.39 (+0.62%) ▲|GE361.61+7.88 (+2.23%) ▲|GEV996.57-18.18 (-1.79%) ▼|GILD130.52+1.21 (+0.94%) ▲|GM87.04+4.40 (+5.32%) ▲|GOOG326.57+7.48 (+2.34%) ▲|GOOGL326.56+6.82 (+2.13%) ▲|GS1,048.23-13.00 (-1.23%) ▼|HD336.09+3.11 (+0.93%) ▲|HON245.75+2.60 (+1.07%) ▲|IBM216.28+2.09 (+0.98%) ▲|INTC91.67-0.65 (-0.70%) ▼|INTU303.91+7.58 (+2.56%) ▲|ISRG356.83+19.33 (+5.73%) ▲|JNJ265.95+2.55 (+0.97%) ▲|JPM356.20+2.99 (+0.85%) ▲|KO84.07+1.82 (+2.21%) ▲|LIN507.02-5.26 (-1.03%) ▼|LLY1,197.53+1.50 (+0.13%) ▲|LMT580.00-2.60 (-0.45%) ▼|LOW211.55+3.91 (+1.88%) ▲|LRCX291.61-13.60 (-4.46%) ▼|MA551.71+12.05 (+2.23%) ▲|MCD270.67+5.91 (+2.23%) ▲|MDLZ60.67+0.15 (+0.25%) ▲|MDT84.22+1.01 (+1.21%) ▲|META593.87-1.32 (-0.22%) ▼|MMM178.23+5.61 (+3.25%) ▲|MO72.89-0.10 (-0.14%) ▼|MRK130.76-0.31 (-0.24%) ▼|MS214.56+0.08 (+0.04%) ▲|MSFT389.10+7.40 (+1.94%) ▲|MU900.20-20.75 (-2.25%) ▼|NEE88.83-0.95 (-1.06%) ▼|NFLX70.40+0.31 (+0.44%) ▲|NKE42.14+0.44 (+1.06%) ▲|NOW105.56+6.78 (+6.86%) ▲|NVDA196.51-10.33 (-4.99%) ▼|ORCL119.90+4.91 (+4.27%) ▲|PEP139.79+3.15 (+2.31%) ▲|PFE24.67+0.13 (+0.53%) ▲|PG148.63+1.22 (+0.83%) ▲|PLTR131.53+8.61 (+7.00%) ▲|PM195.66+2.66 (+1.38%) ▲|QCOM170.04+3.07 (+1.84%) ▲|RTX218.42+5.63 (+2.65%) ▲|SBUX103.65+0.40 (+0.39%) ▲|SCHW104.18+2.21 (+2.17%) ▲|SO96.48-0.77 (-0.79%) ▼|SPG231.67+1.89 (+0.82%) ▲|T24.42+0.29 (+1.20%) ▲|TMO559.53-8.73 (-1.54%) ▼|TMUS177.21-2.88 (-1.60%) ▼|TSLA309.22-3.81 (-1.22%) ▼|TXN279.41-0.17 (-0.06%) ▼|UBER68.18+2.24 (+3.40%) ▲|UNH417.64-3.10 (-0.74%) ▼|UNP299.30-8.02 (-2.61%) ▼|UPS112.95-1.84 (-1.60%) ▼|USB63.49-0.48 (-0.75%) ▼|V362.53+6.79 (+1.91%) ▲|VZ47.32+0.94 (+2.03%) ▲|WFC87.27+0.96 (+1.11%) ▲|WMT111.74+2.27 (+2.07%) ▲|XOM154.77-2.17 (-1.38%) ▼|AAPL336.91+3.89 (+1.17%) ▲|ABBV256.91-2.45 (-0.94%) ▼|ABT104.49+1.43 (+1.39%) ▲|ACN154.06+7.07 (+4.81%) ▲|ADBE237.75+12.64 (+5.62%) ▲|AMAT516.89-19.36 (-3.61%) ▼|AMD494.95-27.00 (-5.17%) ▼|AMGN376.26+0.22 (+0.06%) ▲|AMT166.74+0.07 (+0.04%) ▲|AMZN231.39-0.72 (-0.31%) ▼|AVGO383.22+1.30 (+0.34%) ▲|AXP335.39+9.22 (+2.83%) ▲|BA211.50+1.98 (+0.95%) ▲|BAC62.13+0.08 (+0.13%) ▲|BKNG186.79+9.33 (+5.26%) ▲|BLK1,062.14+6.47 (+0.61%) ▲|BMY62.56+0.47 (+0.76%) ▲|BNY157.77-0.51 (-0.32%) ▼|BRK-B497.18+2.25 (+0.45%) ▲|C133.10+0.91 (+0.69%) ▲|CAT873.28-15.45 (-1.74%) ▼|CL91.98+1.23 (+1.36%) ▲|CMCSA22.80+0.51 (+2.27%) ▲|COF207.05+4.21 (+2.08%) ▲|COP115.58-4.68 (-3.89%) ▼|COST951.58+16.55 (+1.77%) ▲|CRM173.60+9.94 (+6.07%) ▲|CSCO114.57+0.40 (+0.35%) ▲|CVS107.07-0.67 (-0.62%) ▼|CVX190.00-4.79 (-2.46%) ▼|DE625.02-3.14 (-0.50%) ▼|DHR196.50+5.00 (+2.61%) ▲|DIS96.65+1.80 (+1.90%) ▲|DUK128.83-1.69 (-1.29%) ▼|EMR149.30+1.36 (+0.92%) ▲|FDX310.79-4.17 (-1.32%) ▼|GD389.14+2.39 (+0.62%) ▲|GE361.61+7.88 (+2.23%) ▲|GEV996.57-18.18 (-1.79%) ▼|GILD130.52+1.21 (+0.94%) ▲|GM87.04+4.40 (+5.32%) ▲|GOOG326.57+7.48 (+2.34%) ▲|GOOGL326.56+6.82 (+2.13%) ▲|GS1,048.23-13.00 (-1.23%) ▼|HD336.09+3.11 (+0.93%) ▲|HON245.75+2.60 (+1.07%) ▲|IBM216.28+2.09 (+0.98%) ▲|INTC91.67-0.65 (-0.70%) ▼|INTU303.91+7.58 (+2.56%) ▲|ISRG356.83+19.33 (+5.73%) ▲|JNJ265.95+2.55 (+0.97%) ▲|JPM356.20+2.99 (+0.85%) ▲|KO84.07+1.82 (+2.21%) ▲|LIN507.02-5.26 (-1.03%) ▼|LLY1,197.53+1.50 (+0.13%) ▲|LMT580.00-2.60 (-0.45%) ▼|LOW211.55+3.91 (+1.88%) ▲|LRCX291.61-13.60 (-4.46%) ▼|MA551.71+12.05 (+2.23%) ▲|MCD270.67+5.91 (+2.23%) ▲|MDLZ60.67+0.15 (+0.25%) ▲|MDT84.22+1.01 (+1.21%) ▲|META593.87-1.32 (-0.22%) ▼|MMM178.23+5.61 (+3.25%) ▲|MO72.89-0.10 (-0.14%) ▼|MRK130.76-0.31 (-0.24%) ▼|MS214.56+0.08 (+0.04%) ▲|MSFT389.10+7.40 (+1.94%) ▲|MU900.20-20.75 (-2.25%) ▼|NEE88.83-0.95 (-1.06%) ▼|NFLX70.40+0.31 (+0.44%) ▲|NKE42.14+0.44 (+1.06%) ▲|NOW105.56+6.78 (+6.86%) ▲|NVDA196.51-10.33 (-4.99%) ▼|ORCL119.90+4.91 (+4.27%) ▲|PEP139.79+3.15 (+2.31%) ▲|PFE24.67+0.13 (+0.53%) ▲|PG148.63+1.22 (+0.83%) ▲|PLTR131.53+8.61 (+7.00%) ▲|PM195.66+2.66 (+1.38%) ▲|QCOM170.04+3.07 (+1.84%) ▲|RTX218.42+5.63 (+2.65%) ▲|SBUX103.65+0.40 (+0.39%) ▲|SCHW104.18+2.21 (+2.17%) ▲|SO96.48-0.77 (-0.79%) ▼|SPG231.67+1.89 (+0.82%) ▲|T24.42+0.29 (+1.20%) ▲|TMO559.53-8.73 (-1.54%) ▼|TMUS177.21-2.88 (-1.60%) ▼|TSLA309.22-3.81 (-1.22%) ▼|TXN279.41-0.17 (-0.06%) ▼|UBER68.18+2.24 (+3.40%) ▲|UNH417.64-3.10 (-0.74%) ▼|UNP299.30-8.02 (-2.61%) ▼|UPS112.95-1.84 (-1.60%) ▼|USB63.49-0.48 (-0.75%) ▼|V362.53+6.79 (+1.91%) ▲|VZ47.32+0.94 (+2.03%) ▲|WFC87.27+0.96 (+1.11%) ▲|WMT111.74+2.27 (+2.07%) ▲|XOM154.77-2.17 (-1.38%) ▼|
24.9 C
New York
Tuesday, July 28, 2026

Tag: bone mineral density

newssourceFORcompanyinformationcontent1releasesmarket

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH 
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBone mineral density

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers